Abstract: The invention describes a tablet with two end faces and a circumferential face, in which the mutually opposite end faces of the tablet a) overall are nonplanar and are arranged at least approximately parallel to one another, and b) are each provided with a score on the top and bottom sides, the scores lying in the center of the tablet parallel to and above one another.

Abstract: A process for producing solid dosage forms by forming a plastic mixture of at least one polymeric binder, at least one active ingredient and, where appropriate, conventional additives, and shaping the plastic mixture to the solid dosage forms using a mold, wherein an agent which modifies the surface properties is applied in finely divided form to the surface of the plastic, mixture during the shaping is described. The agent which modifies the surface properties is preferably a surfactant, a lipophilic compound, an antioxidant, a coloring agent or an agent with antistatic effect and/or lubricant effect.

Abstract: A novel delayed-release form for pharmaceutical active compounds, characterized by a core containing the active compound and a diffusion-inhibiting, adhesive coating layer having a thickness in the range from 0.01 to 10 .mu.m, consisting of a chemical network which has been applied to the support in a plasma-assisted chemical deposition process, and a process for its production are described.

Abstract: A solid depot drug form produced by melt extrusion at from 50.degree. to 200.degree. C. and continuous shaping of a mixture of from 0.1 to 70% by weight, based on the finished depot form, of a pharmaceutical active ingredient with a polymer melt of the following composition:a) at least 6% by weight, based on the complete depot form, of at least one water-insoluble poly(meth) acrylate with a glass transition temperature Tg in the range from -60.degree. to 180.degree. C.,b) a water-soluble hydroxyalkylcellulose or hydroxy-alkylmethylcellulose with 2 or 3 carbons in the hydroxyalkyl, or an N-vinylpyrrolidone polymer with from 0 to 50% by weight of vinyl acetate or a mixture of the two in the ratio a):b) =5:95 to 95:5, andc) 0-30% by weight, based on the finished depot form, of one or more conventional pharmaceutical auxiliaries.

Abstract: The monohydrochloride and the monomethanesulfonate of amonafide are described. The salts have good pharmaceutical properties besides their antitumor action.

Abstract: An aqueous or pulverulent, water-dispersible pharmaceutical preparation which contains an emulsifier, a protective colloid and, in microdisperse form, an edible oil or fat, a sparingly water-soluble active compound being dissolved in the oil or fat, and a process for its preparation.

Abstract: A hydrophilic theophylline powder formulation consisting of(a) from 5 to 15% by weight of theophylline,(b) from 15 to 30% by weight of lechithin,(c) from 45 to 80% by weight of sugar,(d) from 0 to 5% by weight of a flow agent and(e) from 0 to 30% by weight of further additives, and a process for its preparation.

Abstract: An aqueous or pulverulent, water-dispersible pharmaceutical preparation which contains an emulsifier, a protective colloid and, in microdisperse form, an edible oil or fat, a sparingly water-soluble active compound being dissolved in the oil or fat, and a process for its preparation.

Abstract: Process for the preparation of solid pharmaceutical forms by mixing one or more pharmaceutical active compounds with one or more fusible, pharmacologically tolerated binders and, if required, other conventional pharmaceutical auxiliaries, at from 50.degree. to 180.degree. C., and subjecting the mixture to injection molding or extrusion and shaping, wherein the fusible binder used is a NVP polymer which contains not less than 20% by weight of NVP as copolymerized units, and, where they are present, all of whose comonomers contain nitrogen and/or oxygen.